Gilberto Lopes: Updated ACS Guidelines Put Prostate Cancer Screening and Follow-Up in Focus
Gilberto Lopes/ LinkedIn

Gilberto Lopes: Updated ACS Guidelines Put Prostate Cancer Screening and Follow-Up in Focus

Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn:

“Prostate cancer screening is changing. Now we need to make sure patients benefit.

In my new MedPage Today commentary, I discuss an important shift in the American Cancer Society’s recommendations for prostate cancer screening.

The updated guideline reflects stronger evidence that PSA-based screening can reduce prostate cancer deaths, alongside strategies to limit overdiagnosis and overtreatment.

For average-risk men, the ACS now recommends PSA screening every two years from ages 50 to 69. Black men and men with a strong family history should begin earlier, at age 45, with annual screening.

But the PSA test is only the beginning.

Gilberto Lopes: Updated ACS Guidelines Put Prostate Cancer Screening and Follow-Up in Focus

An elevated PSA should generally be confirmed with repeat testing. MRI and biomarkers can help determine who needs a biopsy. And for many men with low-risk prostate cancer, active surveillance is preferable to immediate treatment.

These advances offer an opportunity to find dangerous cancers earlier while avoiding unnecessary harm.

There is also an important access question. Screening is less useful if patients cannot afford the evaluation following an abnormal result or cannot access timely treatment when necessary.

The success of prostate cancer screening should not be measured simply by how many PSA tests we perform, but by how many lives we save while minimizing unnecessary harm.

Read my new MedPage Today commentary.”

You can also read:

Free PSA vs Total PSA: Understanding Prostate Cancer Risk

Gilberto Lopes: Updated ACS Guidelines Put Prostate Cancer Screening and Follow-Up in Focus